Varespladib

Drug Profile

Varespladib

Alternative Names: A-001; A-002; LY-315920; LY-333013; S-3013; S-5920; Varespladib methyl

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly; Shionogi
  • Developer Anthera Pharmaceuticals; University Health Network
  • Class Acetic acids; Anti-inflammatories; Antirheumatics; Indoles; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute lung injury

Highest Development Phases

  • Discontinued Acute coronary syndromes; Acute lung injury; Coronary artery disease; Multiple organ failure; Systemic inflammatory response syndrome

Most Recent Events

  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Australia (PO)
  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Canada (PO)
  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Czech Republic (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top